---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-26-000084"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2026-10-09T20:16:05+00:00"
generated_at: "2026-10-12T15:09:43.200796+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics pays former CCO Brian Donnelly $1.32M severance; accelerates 2 years of equity vesting

## Summary
- Brian Donnelly, former Chief Commercial Officer, separated Sept 21, 2026; departure from CCO role effective Sept 16, 2026.
- Lump-sum severance of $1,322,294 equals base salary $576,800, target bonus $432,600, and pro-rata FY2026 bonus $312,894.
- Time-based equity awards scheduled to vest within 2 years of separation accelerate, deemed monthly over 24 months; performance awards remain outstanding up to 2 years.
- COBRA premiums paid up to 1 year or until new employment; agreement dated Oct 6, 2026, effective Oct 14, 2026 after 7-day revocation.

## SEC filing metadata
- accession: 0000899923-26-000084
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2026-10-09T20:16:05+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992326000084/0000899923-26-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992326000084/mygn-20261006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-26-000084
- JSON: https://secwatch.observer/filing/0000899923-26-000084.json
- Plain text: https://secwatch.observer/filing/0000899923-26-000084.txt

## Key facts
- Executive change
  Brian Donnelly departed as Chief Commercial Officer at MYRIAD GENETICS INC.
  - Action: departed
  - Role: Chief Commercial Officer
  source text: On October 6, 2026, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Separation Agreement”) with Brian Donnelly, the Company’s former Chief Commercial Officer. As previously disclosed, Mr. Donnelly departed from his position as Chief Commercial Officer of the Company, effective September 16, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992326000084/0000899923-26-000084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.